The FDA's conditional approval of Crofelemer represents a significant achievement for Jaguar Health, as it fills a gap in the veterinary market for treating chemotherapy-induced diarrhea in dogs. This approval not only validates the drug's efficacy and safety but also positions Jaguar Health as a leader in this niche market. The approval is likely to have a positive impact on the company's stock price in the short term, as it opens up new revenue streams and enhances the company's reputation in the pharmaceutical and veterinary sectors.